<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958945</url>
  </required_header>
  <id_info>
    <org_study_id>FloSeal</org_study_id>
    <nct_id>NCT00958945</nct_id>
  </id_info>
  <brief_title>Retrospective Chart Analysis in the Effective Use of FloSeal in Post-Operative Joint Replacements</brief_title>
  <official_title>Retrospective &amp; Prospective Evaluation/Analysis of Hb/Hct in Patients Having Received FloSeal (5ml &amp;10ml) When Undergoing Total Knee or Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Desert Orthopedic Center Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Desert Orthopedic Center Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this analysis is to compare Hemoglobin and Hematocrit levels following total
      hip or knee arthroplasty. The utilization of FloSeal intraoperatively will improve hemostasis
      postoperatively. Decreasing bleeding time will decrease the drop in level of Hemoglobin and
      Hematocrit which usually occurs postoperatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective Analysis of charts on patients having undergone Total Hip or Total Knee
      Arthroplasty. During the patient's hospitalization, lab values of Hg and Hct will be recorded
      for further analysis. Preoperative levels will be also noted to establish baselines.

      Primary Data interest will be Hemoglobin (Hgb) level documented during hospitalization along
      with Hematocrit (HCT) and Red Blood Cell (RBC) data also collected.

      Secondary Data gathered will consist of the following:

        -  patient Demographics

        -  Component Profile

        -  Length of Stay

        -  Anesthesia used

        -  Anesthesiologist

        -  EBL

        -  drain type

        -  Amount of drainage fluid recorded at 12 hour increments until discharge

        -  Amount of FloSeal used

        -  Type of Arthroplasty

           500 patients in Total

        -  100 Historical Control Patients, knees - no FloSeal (retrospective)

        -  100 Patients, knees - 5mL FloSeal (retrospective)

        -  100 Patients, knees- 10mL FloSeal (prospective)

        -  100 Historical Control patients, hips—no FloSeal (retrospective)

        -  100 retrospective patients, hips—5mL of FloSeal (retrospective

      Patients scheduled for Total Knee Arthroplasty will be asked if they wish to participate in
      the part of the study utilizing 10mL of FloSeal. These patient will be consented and the
      their data will be retrospectively gathered.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <arm_group>
    <arm_group_label>FloSeal - Knee - control</arm_group_label>
    <description>100 Historical Control Patients, knees - no FloSeal (retrospective)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FloSeal - Knee - 5ml</arm_group_label>
    <description>100 Patients, knees - 5mL FloSeal (retrospective)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FloSeal - Knee - 10ml</arm_group_label>
    <description>100 Patients, knees- 10mL FloSeal (prospective)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FloSeal - Hip - Control</arm_group_label>
    <description>100 Historical Control patients, hips—no FloSeal (retrospective)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FloSeal - Hip - 5ml</arm_group_label>
    <description>100 retrospective patients, hips—5mL of FloSeal (retrospective)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All Dr. Velyvis's patients that have had a Total Knee or Total Hip after January 1, 2007
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Total Knee and Total Hip Patients

          -  Surgical Time less than 2 hours

        Exclusion Criteria:

          -  Patients who require greater than 2 hour surgeries

          -  Patients who are undergoing revision arthroplasty

          -  Patients with known allergies to materials of bovine origin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H. Velyvis,, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Desert Orthopedic Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Z Cyr, BA</last_name>
    <phone>760-766-1227</phone>
    <email>ccyr@desertortho.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Desert Orthopedic Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <last_update_submitted>August 13, 2009</last_update_submitted>
  <last_update_submitted_qc>August 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>John H. Velyvis, MD</name_title>
    <organization>Desert Orthopedic Center Medical Research Foundation</organization>
  </responsible_party>
  <keyword>Postoperative Hematocrit</keyword>
  <keyword>Postoperative Hemoglobin</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

